| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Over 50% of stroke survivors with documented hypertension do not have their blood pressure controlled. Messerli et al. review data and implications for the PROGRESS trial, which challenges such therapeutic nihilism mandating that all physicians assess and treat hypertension in patients who have had a stroke.
see following
Blood pressure and stroke. . .stroke and blood pressure
Commentary by Barney J. Stern, MD
BP control and stroke are interwoven from several perspectives: 1° stroke prevention, 2° stroke prevention, and acute stroke management. The Views & Reviews article by Messerli et al. emphasizes the importance of BP treatment by the neurologist. PROGRESS shows that BP lowering is effective for 2° stroke prevention for both hypertensive and nonhypertensive patients.
BP therapy is also effective for 1° stroke prevention. The Heart Outcomes Prevention Evaluation (HOPE) study randomized patients at risk for myocardial infarction or stroke to ramipril (an ACE inhibitor) or placebo.1 Treatment was associated with a 38% relative risk reduction for ische-mic stroke and 28% for hemorrhagic stroke.2 Benefits were associated with a mean BP reduction of only 3/2 mm Hg.
The Framingham Heart Studyfound that a systolic BP of 130 to 139 mm Hg or a diastolic BP of 85 to 89 mm Hg conveyed an adjusted 2.5-fold increased risk for women and 1.6-fold increased risk for men for cardiovascular disease, including stroke.3 The mean BP of patients entering the HOPE study was 139/79 mm Hg; 52% of the PROGRESS trial patients had a mean entry BP of 136/79 mm Hg.
Questions remain. 1) Is it all "in the numbers" or are there benefits engendered by BP medications beyond absolute BP? 2) Are there cerebrovascular measures, analogous to left ventricular thickness and creatinine clearance, to guide optimal BP control for stroke prevention? 3) How does BP treatment benefit cognition? 4) What is the risk/benefit of widespread use of BP medications with other medications such as antiplatelet agents, anticoagulants, and statins?
References
1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–153.
2. Probstfield J. American Stroke Association meeting. San Antonio, TX; February, 2002.
3. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001:345:1291–1297.
See the accompanying article by Messerli et al., "Blood pressure control in stroke patients: What should the consulting neurologist advise?" page 23
Linkage analysis of Alzheimer disease and psychosis
When Bacanu et al. examined siblings with concurrent AD and psychotic symptoms, they detected evidence for genetic linkage to three chromosomal regions, two of which have been previously implicated in schizophrenia.
see page 118
The accompanying editorial by Lovestone and Hardy points out that this clever use of a published database still leaves unanswered the question as to whether the coincidence of AD/psychosis represents single loci, or whether there are separate loci with quantitative traits that contribute to AD/psychosis (and possibly to schizophrenia).
see page 11
Clinical outcome in consecutive young adults with ischemic stroke
Leys et al. found low rates of stroke recurrence, myocardial infarction, dependency, and mortality in 287 young adults, 3 years after stroke. Epileptic seizures occurred in 6.6% of patients. Whereas most risk factors were well treated, only one fifth of smokers gave up smoking.
see page 26
Deaths from stroke in US children
Using a national mortality database, Fullerton et al. found that childhood stroke mortality in the United States has declined significantly over the past two decades. Despite this improvement, black children remained at greater risk for death from stroke compared with white children at all time points.
see page 34
The editorial by Kittner accompanying these papers on stroke in the young notes that stroke is twice as common as MS in the 18 to 44 year age group. Although recurrence of stroke is infrequent, the societal cost of stroke disability is very high. Study of stroke in the young may elucidate genetic causes/contributors to etiology because familial aggregation is stronger in early-onset stroke.
see page 6
Neurocognitive sequelae of cancer treatment
The Armstrong et al. prospective study of radiotherapy evaluated cognition and MRI yearly for 6 years in 26 patients with low-grade, supratentorial brain tumors. In half of the patients, MRI white matter hyperintensities and atrophy progressed for 3 years and then stabilized. There was little cognitive decline.
see page 40
Radiologic changes and cognitive performance in low-grade glioma patients
Postma et al. assessed the extent of cerebral radiologic abnormalities in 39 low-grade glioma patients. Cerebral atrophy and white matter changes were observed almost exclusively in patients previously treated with radiotherapy, and correlated with cognitive performance.
see page 121
Intrathecal methotrexate worsens cognitive compromise in children with medulloblastoma
Riva et al. gave children intrathecal methotrexate for medulloblastoma after surgery—-in addition to radiotherapy and systemic chemotherapy. These children had poorer cognitive outcomes than children given the same treatment without intrathecal methotrexate. Because intrathecal methotrexate does not seem to improve survival, its use should be reassessed particularly in children younger than 10 years.
see page 48
The accompanying editorial by Packer and Mehta notes the importance of and the difficulty in studies of effects of treatment in patients with brain tumor. Baseline assessment before any treatment is seldom available. Moreover, most studies including these three have not assessed the impact of treatment on functional outcome or QOL.
see page 8
APOE promoter polymorphisms and Alzheimer disease
Lambert et al. evaluated the impact of the -491 and -219 polymorphisms within the APOE promoter on six independent samples (1,732 AD patients and 1,926 controls). These two polymorphisms were risk factors for AD independently of the 
4 allele.
see page 59
Migraine: Brainstem activation during attacks
Functional MRI-BOLD studies of migraine by Cao et al. showed that an increase in oxygenation and blood volume of red nucleus and substantia nigra was associated with visually triggered symptoms of migraine, suggesting these brainstem structures are part of a neuronal network activated during an attack.
|
see page 72
Vagus nerve stimulation: Effect on itching
Psychophysical studies by Kirchner et al. showed an antipruritic effect of chronic vagus nerve stimulation (VNS), whereas function of peripheral histamine-sensitive C-fibers remained unaltered.
see page 108
Effects of donepezil on learning in normals?
Yesavage et al. report that a group of pilots receiving 5 mg/d donepezil showed significantly greater ability to retain the capacity to perform a set of simulator tasks than the placebo group.
see page 123
Hypokalemia and QT prolongation in women with SAH
SAH often causes hypokalemia and QT prolongation in acute SAH. Fukui et al. demonstrated that women are more prone than men to develop hypokalemia and QT prolongation on the first day following SAH.
see page 134
Nisus: Neurology and the Humanities: "The Rubato Queen"
Carl Ellenberger’s vignette captures (in the words of reviewer Bruce Sigsbe) "the humanity which we risk losing in science."
|
see page 145
This article has been cited by other articles:
|
|
 |
|
  W. J. Hader and I. M.L. Yee Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan Neurology, September 18, 2007; 69(12): 1224 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Boulet, E. Lacombe, C. Carcenac, C. Feuerstein, V. Sgambato-Faure, A. Poupard, and M. Savasta Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata. J. Neurosci., October 18, 2006; 26(42): 10768 - 10776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Katz Methodological issues in clinical trials of opioids for chronic pain Neurology, December 29, 2005; 65(12_suppl_4): S32 - S49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Zesiewicz, R. Elble, E. D. Louis, R. A. Hauser, K. L. Sullivan, R. B. Dewey Jr, W. G. Ondo, G. S. Gronseth, and W. J. Weiner Practice Parameter: Therapies for essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, June 28, 2005; 64(12): 2008 - 2020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Charlier, H. Nunes, J-C. Trinchet, E. Roullet, L. Mouthon, M. Beaugrand, and D. Valeyre Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease Eur. Respir. J., March 1, 2005; 25(3): 570 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. LUNA and J. A. SWEENEY The Emergence of Collaborative Brain Function: fMRI Studies of the Development of Response Inhibition Ann. N.Y. Acad. Sci., June 1, 2004; 1021(1): 296 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Volk, V. Gorboulev, T. Budiman, G. Nagel, and H. Koepsell Different Affinities of Inhibitors to the Outwardly and Inwardly Directed Substrate Binding Site of Organic Cation Transporter 2 Mol. Pharmacol., November 1, 2003; 64(5): 1037 - 1047. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
